MetaCap

AgomAb Therapeutics NV (AGMB) vs Eikon Therapeutics (EIKN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $256.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%EIKN-67.31%
+26%-23%-72%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%EIKN-67.31%
+13%-29%-71%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus EIKN key metrics
MetricAGMBEIKN
Share price$5.45$4.74
Market cap$268.40M$256.84M
1-day change-3.02%-0.42%
EPS (TTM)$-2.08$-7.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$17.82$17.40
52-week low$5.39$4.72
Distance from 52-week high-69.42%-72.76%
Analyst consensusstrong_buybuy
Avg. price target upside+591.19%+406.33%
Average volume208.99K560.40K
Shares outstanding49.25M54.19M
Employees62384
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

AGMB vs EIKN FAQ

Which is bigger, AgomAb Therapeutics NV or Eikon Therapeutics?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $256.84M for Eikon Therapeutics (EIKN).

Are AgomAb Therapeutics NV and Eikon Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons